Electrophysiology CINRE, hospital BORY
Atrial Fibrillation: Guidelines (2026) Compendium / 3.1 Epidemiology and Economic Burden of Atrial Fibrillation

Epidemiology and Economic Burden of Atrial Fibrillation


Atrial fibrillation (AF) is the most common arrhythmia,

  • the prevalence in the general population is 2–4 %.

The prevalence of AF increases with age. AF affects:

  • 2 % of individuals aged <65 years
  • 9 % of individuals aged >65 years

Prevalence of AF in individual countries:

  • Slovakia (150 000)
  • Portugal (250 000)
  • Japan (1 000 000)
  • France (1 000 000)
  • Spain (1 000 000)
  • Poland (1 000 000)
  • South Korea (1 000 000)
  • Italy (1 200 000)
  • United Kingdom (1 600 000)
  • Germany (2 000 000)
  • Russia (3 700 000)
  • Arab countries (5 000 000)
  • USA (10 000 000)
  • China (12 000 000)
  • India (15 000 000)
Infographic illustrating the prevalence of atrial fibrillation across individual countries worldwide, expressed as a percentage of the population.
Prevalence of atrial fibrillation
Atrial fibrillation is the most common arrhythmia; the prevalence in the general population is 2–4 %.

The prevalence of AF increases with age. AF affects:

  • 2 % of individuals aged <65 years
  • 9 % of individuals aged >65 years

Annual costs per patient with AF are €1000 – 10 000 (depending on the country):

  • hospitalizations, interventional procedures, specialist consultations,
  • pharmacological therapy, post-complication care (stroke), rehabilitation
Prevalence and Economic Burden of Atrial Fibrillation
Country Number of patients Annual treatment costs
Slovakia 150 000 €210 mil.
Portugal 250 000 €350 mil.
Japan 1 000 000 €1 000 mil.
France 1 000 000 €2 600 mil.
Spain 1 000 000 €1 500 mil.
Poland 1 000 000 €2 000 mil.
Italy 1 200 000 €1 500 mil.
South Korea 1 000 000 €1 300 mil.
United Kingdom 1 600 000 €1 250 mil.
Germany 2 000 000 €1 650 mil.
Russia 3 700 000 €6 000 mil.
Arab countries 5 000 000 €8 000 mil.
USA 10 000 000 €38 000 mil.
China 12 000 000 €12 000 mil.
India 15 000 000 €4 000 mil.

These guidelines are unofficial and do not represent formal guidelines issued by any professional cardiology society. They are intended for educational and informational purposes only.

Peter Blahut, MD

Peter Blahut, MD (Twitter(X), LinkedIn, PubMed)